期刊文献+

高效液相色谱-串联质谱法测定 减肥保健食品中违禁添加药物利莫那班 被引量:1

HPLC-MS/MS Determination of the Contraband Drug Rimonabant Added in De-obese Health-care Foodstuffs
下载PDF
导出
摘要 提出了减肥保健食品中违禁添加药物利莫那班的高效液相色谱-串联质谱分析方法。不同类型的减肥保健食品经加速溶剂萃取及固相萃取净化后,以Waters Atlantis T_3分离柱,以甲醇-10 mmol·L^(-1)乙酸铵混合溶液为流动相,采用多反应监测正离子模式检测,定性离子对为m/z462.9,363.0,m/z 462.9,84.0,定量离子对为m/z 462.9,363.0。线性范围为0.2~500μg·L^(-1),检出限(3S/N)为0.75 mg·kg^(-1)。加标回收率为83.7%~101.6%,日内和日间精密度(n=6)分别小于8%和10%。 HPLC-MS/MS was applied to the determination of rimonabant, a contraband drug added in some de-obese health-care foodstuffs. Rimonabant in different kinds of such foodstuffs were separated from the sample and purified by accelerated solvent extraction and solid phase extraction in succession. The eluate was used for HPLC-MS/MS determination, in which the Waters Atlantis T3 column was used as chromatographic column, and a mixture of methanol and 10 mmol · L^-1 ammonium acetate solution was used as mobile phase; positive electrospray ionization as well as multiple reaction monitoring mode was used in the detection. Ion pairs used for qualitative analysis were: m/z 462. 9, 363. 0 and m/z 462. 9, 84. 0, ion pair use for quantitative analysis was m/z 462. 9, 363.0. Linearity range was found between 0. 2- 500 μg · L^-1, and the detection limit (3S/N) found was 0. 75 mg · kg^-1. Values of recovery found by addition of standard rimonahant, were in the range of 83. 7%- 101.6%, and values of RSD's (n=6) of intra-day and inter-day found were less than 8% and 10% respectively.
出处 《理化检验(化学分册)》 CAS CSCD 北大核心 2009年第10期1145-1149,共5页 Physical Testing and Chemical Analysis(Part B:Chemical Analysis)
基金 国家科技支撑计划农业领域课题(2006BAD27B02)
关键词 高效液相色谱-串联质谱 利莫那班 减肥保健食品 HPLC MS/MS Rimonabant De-obese health care foodstuffs
  • 相关文献

参考文献11

  • 1PAGOTTO U, PASQUALI R, VAN G L K Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO- Europe study[J]. Lancet, 2005, 365 (9468): 1389- 1397. 被引量:1
  • 2POIRIER P B, BIDOUARD J P, CADROUVELE C. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile[J]. Diabetes Obes Metab, 2005,7(1) : 65-72. 被引量:1
  • 3SERENAT. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors [J]. Nutrition, Metabolism & Cardiovascular Diseases, 2006,16 : 156-162. 被引量:1
  • 4RINALDI-CARMONA M, BARTH F, HEAULME M 1. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor [J]. FEBS Lett, 1994, 350(3) : 240-244. 被引量:1
  • 5KOTAGIRI V K, JAMBULA M R, SASHI K S, et al. Synthesis of rimonabant regioisomer [J]. Monatsh Chem, 2008,139: 1091-1093. 被引量:1
  • 6吴火华,李少华.利莫那班合成路线图解[J].中国医药工业杂志,2008,39(7):548-550. 被引量:3
  • 7MELISSA M, ZHOU Xiang, XU Yan, et al. Determination of endocannabin-oid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatographtandem mass spectrometry[J]. Chromatography, 2008,863 : 258-265. 被引量:1
  • 8STANISLAS G D, EMURI A, PHILIPPE D, et al. Determination of rimonabant in human plasma and hair by liquid chromatography-mass spectrometry [J]. Chromatography, 2008,872: 115-120. 被引量:1
  • 9王光辉,熊少祥编著..有机质谱解析[M].北京:化学工业出版社,2005:194.
  • 10苏克曼 ... ..波谱解析法[M],2002.

二级参考文献11

  • 1汤立合,陶林,陈合兵,仲伯华.盐酸利莫那班的合成[J].中国医药工业杂志,2007,38(4):252-254. 被引量:10
  • 2Pagotto U, Pasquali R, Van Gaal LF, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study [J]. Lancet, 2005, 365 (9468) : 1389-1397. 被引量:1
  • 3Poirier B, Bidouard JP, Cadrouvele C. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile [J]. Diabetes, Obes Metab, 2005, 7 (1) : 65-72. 被引量:1
  • 4Barth F, Casellas P, Congy C, et al. Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present: US, 5624941 [P]. 1997-04-29. (CA 1997, 127: 5085) 被引量:1
  • 5Seltzman HH, Carroll FI, Burgess JP, et al. Synthesis, spectral studies and tritiation of the cannabinoid antagonist SR141716A [J]. J Chem Soc, Chem Commun, 1995, (15): 1549-1550. 被引量:1
  • 6Seltzman HH, Carroll FI, Burgess JP, et al. Tritiation of SRI 41716 by metalation-iodination-reduction: tritium-proton noe study [J]. J Labell Comp Radio, 2002, 45 (1) : 59-70. 被引量:1
  • 7Thomas BF, Seltzman HH, Francisco MEY. Compounds having unique CBI receptor binding selectivity and methods for their production and use: US, 20030199536 [P]. 2003-10-23. (CA 2003, 139:317464) 被引量:1
  • 8Kotagiri VK, Suthrapu S, Reddy JM, et al. An improved synthesis of rimonabant: anti-obesity drug [J]. Org Process ResDev, 2007, 11 (5): 910-912. 被引量:1
  • 9Dutta AK, Sard H, Ryan W, et al. The synthesis and pharmacological evaluation of the cannabinoid antagonist SR 141716A [J]. Med Chem Res, 1995, 5 (1) : 54-62. 被引量:1
  • 10Marc D, Alain D, Philippe V, et al. Method for preparing N-piperidino- 1,5-diphenylpyrazole- 3 -carboxamide derivatives: WO, 2006021652 [P]. 2006-03-02. (CA 2006, 144: 170983) 被引量:1

共引文献2

同被引文献17

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部